WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported a wider third-quarter loss and a 52% decline in total revenue as clinical development expenses increased, even as sales of …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.